BR112014005064A2 - não solvatos de sal de norigobaína - Google Patents

não solvatos de sal de norigobaína

Info

Publication number
BR112014005064A2
BR112014005064A2 BR112014005064A BR112014005064A BR112014005064A2 BR 112014005064 A2 BR112014005064 A2 BR 112014005064A2 BR 112014005064 A BR112014005064 A BR 112014005064A BR 112014005064 A BR112014005064 A BR 112014005064A BR 112014005064 A2 BR112014005064 A2 BR 112014005064A2
Authority
BR
Brazil
Prior art keywords
solvates
norigobaain
salt
norigobain
salt non
Prior art date
Application number
BR112014005064A
Other languages
English (en)
Inventor
D Gless Richard
C Schinzer William
Original Assignee
Demerx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47881233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014005064(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Demerx Inc filed Critical Demerx Inc
Publication of BR112014005064A2 publication Critical patent/BR112014005064A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo patente de invenção: "não solvatos de sal de norigobaína". não solvatos de sal de norigobaína estáveis são úteis para preparar composições farmacêuticas e para aliviar dor nociceptiva em um paciente. tais não solvatos podem ser preparados por suspender como lama formas solvatadas, preferencialmente cloridrato de norigobaína solvatado por meoh em etoh/água.
BR112014005064A 2011-09-15 2012-09-14 não solvatos de sal de norigobaína BR112014005064A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535300P 2011-09-15 2011-09-15
PCT/US2012/055597 WO2013040471A2 (en) 2011-09-15 2012-09-14 Noribogaine salt ansolvates

Publications (1)

Publication Number Publication Date
BR112014005064A2 true BR112014005064A2 (pt) 2017-04-04

Family

ID=47881233

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014005064A BR112014005064A2 (pt) 2011-09-15 2012-09-14 não solvatos de sal de norigobaína

Country Status (18)

Country Link
US (4) US9040520B2 (pt)
EP (1) EP2755658A4 (pt)
KR (2) KR20140062472A (pt)
CN (2) CN103857397B (pt)
AU (1) AU2012308274B2 (pt)
BR (1) BR112014005064A2 (pt)
CA (1) CA2845007C (pt)
CL (1) CL2014000506A1 (pt)
CO (1) CO6970589A2 (pt)
HK (1) HK1199840A1 (pt)
IL (1) IL230940B (pt)
MX (1) MX2014001933A (pt)
PE (1) PE20142353A1 (pt)
RU (1) RU2014105881A (pt)
SG (1) SG2014011811A (pt)
TW (2) TWI588145B (pt)
WO (1) WO2013040471A2 (pt)
ZA (1) ZA201401268B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765737B1 (en) * 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9394294B2 (en) * 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US9358237B2 (en) 2010-07-23 2016-06-07 Demerx, Inc. Noribogaine compositions
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
US9040520B2 (en) 2011-09-15 2015-05-26 Demerx, Inc. Noribogaine salt ansolvates
WO2013085922A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
HUE035069T2 (en) 2011-12-28 2018-05-02 Global Blood Therapeutics Inc Substituted benzaldehyde compounds and their use to increase tissue oxygenation
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US8877921B2 (en) 2012-01-25 2014-11-04 Demerx, Inc. Synthetic voacangine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
JP2016508979A (ja) 2012-12-20 2016-03-24 デメレックス， インコーポレイテッド 置換ノルイボガイン
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2014143201A1 (en) 2013-03-15 2014-09-18 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
KR20150132146A (ko) 2013-03-15 2015-11-25 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2903022C (en) 2013-03-15 2021-11-09 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
PE20161035A1 (es) 2013-03-15 2016-11-13 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulacion de la hemoglobina
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
JP6809681B2 (ja) 2014-02-07 2021-01-06 グローバル ブラッド セラピューティクス インコーポレイテッド ２−ヒドロキシ−６−（（２−（１−イソプロピル−１ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形
AU2014383143A1 (en) 2014-02-18 2016-09-29 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
US9345711B2 (en) 2014-02-18 2016-05-24 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
PT3223906T (pt) 2014-11-26 2021-05-05 Demerx Inc Métodos e composições para potencializar a ação de analgésicos de opioides usando alcaloides de iboga
TW201731509A (zh) 2015-12-04 2017-09-16 全球血液治療公司 針對２-羥基-６-（（２-（１-異丙基-１ｈ-吡唑-５-基）吡啶-３-基）甲氧基）-苯甲醛之劑量方案
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
EP3955936A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Treatment of depression and other various disorders with psilocybin
WO2023150547A2 (en) * 2022-02-01 2023-08-10 Caamtech, Inc. Psychedelic compounds and their therapeutic uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2813873A (en) * 1957-11-19 Derivatives of the ibogaine alkaloids
GB789870A (en) * 1955-10-10 1958-01-29 Gobey Lab Alkaloid derivatives
MX9701430A (es) * 1994-07-25 1997-12-31 Nda Int Inc Un metodo de tratamiento de dependencia quimica en mamiferos y una composicion para el mismo.
US5591738A (en) * 1994-10-14 1997-01-07 Nda International, Inc. Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof
EP2246058A1 (en) 1997-09-04 2010-11-03 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
RU2005117630A (ru) * 2002-11-08 2006-01-20 Дов Фармасьютикал, Инк. (Us) Полиморфы гидрохлорида бицифадина
AU2007209992A1 (en) * 2006-01-31 2007-08-09 Thallion Pharmaceuticals Inc. Crystalline forms of a farnesyl dibenzodiazepinone
US9358237B2 (en) * 2010-07-23 2016-06-07 Demerx, Inc. Noribogaine compositions
EP2481740B1 (en) * 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9040520B2 (en) 2011-09-15 2015-05-26 Demerx, Inc. Noribogaine salt ansolvates

Also Published As

Publication number Publication date
TWI588145B (zh) 2017-06-21
IL230940B (en) 2022-04-01
CA2845007C (en) 2020-09-29
US9617265B2 (en) 2017-04-11
KR20200115661A (ko) 2020-10-07
KR20140062472A (ko) 2014-05-23
MX2014001933A (es) 2014-03-27
WO2013040471A3 (en) 2013-05-10
US20160108043A1 (en) 2016-04-21
RU2014105881A (ru) 2015-10-20
IL230940A0 (en) 2014-03-31
NZ620948A (en) 2016-10-28
US20130072472A1 (en) 2013-03-21
US20170022194A1 (en) 2017-01-26
CN105949193A (zh) 2016-09-21
KR102381792B1 (ko) 2022-04-01
US9040520B2 (en) 2015-05-26
EP2755658A4 (en) 2015-03-18
CO6970589A2 (es) 2014-06-13
SG2014011811A (en) 2014-05-29
CN103857397B (zh) 2016-08-17
PE20142353A1 (es) 2015-01-10
WO2013040471A2 (en) 2013-03-21
TW201313720A (zh) 2013-04-01
EP2755658A2 (en) 2014-07-23
US20170022193A1 (en) 2017-01-26
CN103857397A (zh) 2014-06-11
HK1199840A1 (en) 2015-07-24
ZA201401268B (en) 2016-11-30
CA2845007A1 (en) 2013-03-21
TW201726676A (zh) 2017-08-01
AU2012308274B2 (en) 2017-08-17
AU2012308274A1 (en) 2014-02-27
CL2014000506A1 (es) 2014-08-22

Similar Documents

Publication Publication Date Title
BR112014005064A2 (pt) não solvatos de sal de norigobaína
TN2013000321A1 (en) C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
MX2015011955A (es) Lipidos y composiciones de lipidos para el suministro de agentes activos.
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
IN2014DN09434A (pt)
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
MA33939B1 (fr) 5-alcynyl-pyrimidines
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
IN2012DN03328A (pt)
NZ725781A (en) Pesticidal compositions and related methods
MY158257A (en) Forms of rifaximin and uses thereof
PH12015501609A1 (en) Phenicol antibacterials
BR112014027117A2 (pt) derivados de pirazol aminopirimidina como moduladores de lrrk2 para uso no tratamento de doença de parkinson
MX359288B (es) Forma iv del clorhidrato de ivabradina.
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
MX2009013501A (es) Compuestos piperidinicos y sus usos.
MX340233B (es) Agonistas de receptores de neurotrofina y sus usos como medicamentos.
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
MX2015007053A (es) Compuestos dimericos.
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
BR112014002173A2 (pt) proteínas purificadas
EA201201109A1 (ru) Прасугрель в тонкоизмельченной кристаллической форме и фармацевтическая композиция, содержащая его
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
MX347620B (es) Derivados de sulfonilaminopirrolidinona, su preparacion y aplicacion terapeutica.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2479 DE 10-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI